STOCK TITAN

Accolade Inc - ACCD STOCK NEWS

Welcome to our dedicated news page for Accolade (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Accolade's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Accolade's position in the market.

Rhea-AI Summary
Accolade, Inc. (ACCD) to Present at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
conferences
-
Rhea-AI Summary
Accolade, Inc. (NASDAQ: ACCD) announced the repurchase of approximately $76.5 million aggregate principal amount of its outstanding 0.50% Convertible Senior Notes due 2026 for an aggregate cash repurchase price of approximately $65.8 million. The company aims to strengthen its balance sheet and improve its net cash position through this strategic move, positioning itself for long-term financial and strategic success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
buyback
-
Rhea-AI Summary
Accolade, Inc. (NASDAQ: ACCD) to Present at Stephen Annual Investment Conference on November 15, 2023. Webcast and replay available at ir.accolade.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences
Rhea-AI Summary
Accolade (ACCD) Achieves 227% Revenue Growth, Named to Deloitte Technology Fast 500™ List
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
none
-
Rhea-AI Summary
Accolade announces findings from employer survey on sentiment and adoption of GLP-1 medications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
none
-
Rhea-AI Summary
Accolade, Inc. announces strong demand for its solutions and a growing customer base of over 1,000 customers. Financial highlights for the fiscal second quarter show an 11% increase in revenue to $96.9 million and a net loss of $32.8 million, a 29% improvement. Adjusted EBITDA improved by 36% to $(8.8) million. Accolade expects cost reduction measures to lead to profitability in the second half of the year. Forward-looking guidance for the fiscal third quarter includes revenue between $95 million and $97 million and Adjusted EBITDA between $(5) million and $(8) million. For the fiscal year ending February 29, 2024, revenue is expected to be between $410 million and $414 million, with Adjusted EBITDA between $(6) million and $(12) million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.13%
Tags
Rhea-AI Summary
Accolade, Inc. (NASDAQ: ACCD) to release fiscal Q2 2024 results on October 4, 2023 after market closes. Conference call to review results at 4:30 p.m. E.T. on the same day. Replay available for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
-
Rhea-AI Summary
Accolade expands care delivery team with new leadership roles
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
none
-
Rhea-AI Summary
Accolade, Inc. (NASDAQ: ACCD) to present at upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
conferences
Rhea-AI Summary
Accolade, Inc. to present at investor conferences, webcast available
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
conferences
Accolade Inc

Nasdaq:ACCD

ACCD Rankings

ACCD Stock Data

650.22M
69.64M
2.99%
88.18%
4.14%
All Other Information Services
Information
Link
United States
Plymouth Meeting

About ACCD

accolade is a personalized health and benefits solution that dramatically improves the experience, outcomes and cost of healthcare for employers, health plans and their members. with a unique blend of compassionate advisors, clinical experts and intelligent technologies, we engage individuals and families in their health, establish trust, and influence their decisions at every stage of care. we’ve been recognized as one of the nation’s 25 most promising companies by forbes magazine, the fastest-growing private healthcare company by inc. 500, and a top workplace by multiple news publications. for more information, visit www.accolade.com.